Evidence map›Paper›PMID 42511467›Full record

ArticleInternational journal of molecular sciences2026

Targeting CDK2 and AURKA with Cerevisterol from

Yi Pan, Xuewei Wu, Lin Chen, Chao Zhang, Yuqing Hu, Jie Chang, Qiuwen Lou, Jiaqi Zhang, Shuochen Xu, Wenxia Xu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi PanCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.ORCID 0000-0002-0725-5685
Xuewei WuCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.ORCID 0000-0003-1047-0041
Lin ChenCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.
Chao ZhangCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.
Yuqing HuCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.ORCID 0009-0000-7564-1417
Jie ChangCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.
Qiuwen LouCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.
Jiaqi ZhangCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.
Shuochen XuCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.
Wenxia XuCentral Laboratory, Precision Medicine Center, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.
Jianping WangDepartment of Colorectal Surgery, National Clinical Key Disciplines, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.

Funding

Jinhua Municipal Science and Technology Bureau No. 2023-3-111Jinhua Municipal Science and Technology Bureau No. 2025-03-004Jinhua Municipal Science and Technology Bureau No. 2026-3-039National Natural Science Foundation of China No. 82373354Zhejiang Provincial Natural Science Foundation No.JHSZ26H160001Zhejiang Provincial Natural Science Foundation No. LTGY23H160025
6 · The paper itself

Abstract

Chemotherapy resistance remains a major challenge in colorectal cancer (CRC) treatment, necessitating novel adjuvant strategies. This study employed an integrated analytical strategy combining network pharmacology, single-cell RNA sequencing (scRNA-seq) of patient-derived organoids (PDOs) and molecular dynamics simulations to identify bioactive compounds from

Indexed as

Aurora Kinase AColorectal NeoplasmsCyclin-Dependent Kinase 2ReishiSterolsCell Line, TumorDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMolecular Dynamics SimulationAURKA protein, humanAurora Kinase ACDK2 protein, humanCyclin-Dependent Kinase 2SterolsCDK2 and AURKAcerevisterolcolorectal cancerGanoderma lucidumnetwork pharmacologysingle-cell RNA sequencing

Identifiers

PMID42511467
PMCPMC13411116

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.